Verastem Oncology (VSTM) – Major News
-
Verastem Oncology (VSTM) Misses Q4 EPS by 102c
-
Verastem Oncology (VSTM) Tops Q3 EPS by 8c
-
Verastem (VSTM) Misses Q2 EPS by 26c
-
Verastem (VSTM) Misses Q1 EPS by 1c
-
Verastem (VSTM) Tops Q4 EPS by 2c
-
Verastem (VSTM) Tops Q3 EPS by 11c
-
Verastem (VSTM) Misses Q2 EPS by 7c
-
Verastem (VSTM) Misses Q1 EPS by 5c, Revenues Miss; FY19 Revenue Guidance Below Consensus
-
Verastem (VSTM) Reports Q4 Loss Per Share of 37c
-
Verastem (VSTM) Confirms FDA Approval of COPIKTRA (duvelisib)
-
Verastem (VSTM) Tops Q3 EPS by 3c
-
Verastem (VSTM) Tops Q2 EPS by 6c
-
Verastem (VSTM) Plans 50% Workforce Reduction
-
Verastem (VSTM) Ceases VS-6063 Phase 2 Enrollment in Mesothelioma Following DSMB Recommendation
-
Verastem (VSTM) Tops Q2 EPS by 3c
-
Verastem (VSTM) Reports Q1 Loss of $0.46/Share
-
Verastem Shs (VSTM) Posts Q2 Loss of 49c/Share
-
Verastem (VSTM) Promotes Robert Forrester to CEO
-
Verastem Shs (VSTM) Posts Q1 Loss of 44c/Share
-
Verastem Shs (VSTM) Reports In-Line Q2 Loss of 34c/Share
-
Verastem (VSTM) IPO Trades Higher
Back to VSTM Stock Lookup